Anavex Life Sciences Corp (AVXL)

[nidan7500]

Will AI be able to look at all the biomarkers and results tweeking another bread crumb in the search for AD? And conversely will AI look at AD progression and pick up on shared similarities with PD, PDD, MS, Epilepsy?

We are on the same thread ref:this process of proof/discovery/learning. IMO, PDD may present evidence for verification supporting the CNS cellular homeostasis dynamic model discussed here. As that occurs AI should be of value to map all variables helping to keep it all on track. It may be that if the AI models are capable of self learning then it could go along quickly well. They may not have to go back to the bench. Getting proof that the A2-73 treatment does what is expected is key, that IMO is what is different about what Dr. M and team are doing. Hope this makes sense. It is not only about clinical trial (patient results) but it is also about the breakthrough learning. Connecting the dots will be an experience that these people live for. Bless them all.